Ranbaxy Laboratories files complaint against USFDA for revoking approved drugs

19 Nov 2014 Evaluate

Ranbaxy Laboratories has filed a complaint against the US Food and Drug Administration (USFDA) in D.C. federal court and has also asked the Court for a temporary restraining order to prevent any further action by USFDA until Ranbaxy’s case is decided. The pharma major has filed a complaint following, and in response to, the revocation of Ranbaxy’s tentative approvals for Ranbaxy’s ANDAs for esomeprazole magnesium delayed-release capsules and valganciclovir hydrochloride tablets.

Earlier this month, the USFDA withdrew its decision to grant tentative approvals to Ranbaxy for the two generic drugs citing the compliance status of Ranbaxy production facilities. The regulator had stated that its original decisions were in error because it found Ranbaxy’s plants at the time were not compliant with the regulatory norms.

Ranbaxy Laboratories is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.

Peers
Company Name CMP
Sun Pharma Inds. 1540.30
Dr. Reddys Lab 5872.65
Cipla 1481.55
Zydus Lifesciences 1076.45
Lupin 1712.05
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.